Highlights

  • ImmunityBio shares closed up 30.79% on Thursday following preliminary 2025 revenue disclosures
  • Trading volume surged more than fourfold compared with the three-month average
  • Anktiva sales projections and regulatory developments drew market attention

Shares of ImmunityBio Inc. (NASDAQ:IBRX) closed Thursday’s session at USD 3.95, marking a 30.79% gain for the day. The move followed the company’s release of preliminary full-year 2025 results, which outlined a substantial increase in revenue from its bladder cancer therapy, Anktiva. Over the past five trading sessions, the stock has risen 74.78%, reflecting heightened short-term activity around recent company updates.

After regular trading hours, ImmunityBio shares continued to move higher, last trading at USD 4.77, up 20.76% in after-hours activity, according to market data.

Trading Volume Spikes Well Above Average

Thursday’s rally was accompanied by a sharp rise in trading activity. Approximately 70.4 million shares changed hands during the session, representing about 442% of the stock’s three-month average volume of roughly 13 million shares. The elevated volume suggested increased participation following the release of updated revenue expectations and regulatory developments.

Despite the recent gains, ImmunityBio shares remain significantly below historical levels. The company went public in 2015, and the stock has declined approximately 89% since its initial public offering, highlighting the contrast between long-term performance and recent price movements.

Revenue Update Centers on Anktiva

According to management’s preliminary projections, ImmunityBio expects Anktiva revenue to rise from USD 15 million in 2024 to approximately USD 113 million, representing growth of roughly 700% year over year. Management also indicated that quarterly sales increased by 20% compared with the prior quarter, contributing to the stronger-than-expected performance.

The sales update followed a series of developments tied to Anktiva. One day prior to Thursday’s rally, the Saudi Food and Drug Authority approved Anktiva for use in the country, which coincided with an earlier share-price increase. Earlier in the week, the company also released positive data for Anktiva in non-small cell lung cancer, a potential additional indication.

Broader Market and Sector Context

U.S. equity markets closed modestly higher on Thursday. The S&P 500 added 0.27% to close at 6,945, while the Nasdaq Composite rose 0.25% to 23,530. Within the biotechnology sector, peers moved in the opposite direction. Incyte closed at USD 105.24, down 0.67%, while Vertex Pharmaceuticals ended at USD 438.92, down 2.36%, both lagging ImmunityBio’s sharp advance.

What the Market Is Watching

Recent price action has been closely tied to revenue visibility, regulatory approvals, and clinical data updates related to Anktiva. With ongoing attention on demand trends, geographic expansion, and potential label extensions, ImmunityBio’s share price has shown heightened sensitivity to company-specific announcements, underscoring the stock’s near-term volatility.